Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06013475 · ClinicalTrials.gov registry record
An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 1,375
- Enrollment target
NCT06013475 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 1,375 participants.
The verdict
NCT06013475 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 1,375 participants
- Enrollment target
Study Summary
This is an observational cohort study in men with non-metastatic castration-resistant prostate cancer who received their usual treatment, which is 'Androgen receptor inhibitors' (ARIs) including darolutamide, enzalutamide, and apalutamide. The main purpose of this study is to collect data on the length of time men with nmCRPC continued treatment with darolutamide, enzalutamide, or apalutamide as prescribed by their doctors. Researchers will only include men who had not been treated with any new type of medication that blocks the action of hormones. The data will come from an electronic health record database called Precision Point Specialty (PPS) Prostate Cancer Electronic Medical Record (EMR) for men in the United States of America. EMR data will be verified and supplemented via patient chart review. Data collected will be from January 2019 to September 2023. .
Interventions
- DRUG Apalutamide
- DRUG Enzalutamide
- DRUG Darolutamide (BAY 1841788)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,375 participants |
| Start Date | 2023-08-31 |
| Est. Completion | 2024-10-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06013475
The ClinicalTrials.gov registry entry for NCT06013475 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,375 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Apalutamide is the first listed.
NCT06013475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06013475 about?
NCT06013475 is a clinical study titled "An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings". This is an observational cohort study in men with non-metastatic castration-resistant prostate cancer who received their usual treatment, which is 'Androgen receptor inhibitors' (ARIs) including darolutamide, enzalutamide, and apalutamide. The main purpose of this study is to collect data on the le...
What is the current status of trial NCT06013475?
This trial is currently completed. The enrollment target is 1,375 participants. The study started on 2023-08-31. Estimated completion is 2024-10-28.
What interventions are being tested in trial NCT06013475?
The interventions under investigation include: Apalutamide (DRUG), Enzalutamide (DRUG), Darolutamide (BAY 1841788) (DRUG).
Who is sponsoring clinical trial NCT06013475?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.